Our Portfolio of Companies

Enabling disruptive scientific changes.

Our unique approach ensures our portfolio companies are creating game changing revolutionary science, actively building collaborative working relationships with our companies to help them grow. As a result, we don’t just invest, we partner to enable disruptive scientific changes helping patients live better lives.

Alpine Immune Sciences

We founded and seed funded Alpine Immune Sciences in 2015 to lead the next evolution of immunotherapies. The company was created to capitalize on the founders’ unique understanding of immunology, creating protein-based multispecific immunotherapies targeting the immune synapse to treat cancer and autoimmune/inflammatory disorders. The company closed its Series A funding of $48M in June 2016 (press release). The company became publicly traded in July 2017 (press release) on the NASDAQ under the ticker symbol ‘ALPN’. In June 2020, the company signed a transformative option and license agreement with AbbVie for the development and commercialization of ALPN-101 (press release)

Angion Biomedica

ABV became a significant equity holder in Angion in May 2018 as compensation for Jay Venkatesan serving as the interim CEO. Angion is a private company focused on therapeutics to prevent acute organ injury and reverse fibrosis in chronic organ injuries, with a particular focus on kidney injuries. The company’s lead product, ANG-3777, was developed as a small molecule mimetic of the hepatocyte growth factor protein based on the decades of research the company’s founder has spent investigating this pathway. ANG-3777 is in Phase III for the treatment of delayed graft function following kidney transplantation and in Phase II for the prevention and mitigation of acute kidney injury in high-risk patients undergoing cardiovascular surgery. ANG-3777 and the other pipeline products have been developed with the assistance of more than $65 million in NIH, DOD, and other government grants, as well as nearly $50 million in equity raised to-date. The company recently announced a license and collaboration agreement with Sinovant Sciences to develop and commercialize ANG-3777 in Greater China.

Mavupharma logo


We joined Frazier Healthcare to make a $20M Series A round investment in November 2017. Mavu is developing oral non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. Mavu was acquired by AbbVie in July 2019. (Press release)

Acquired by

We founded Alpine Biosciences in 2012 to develop ‘protocells’, a unique nanoparticle platform technology licensed from the University of New Mexico and Sandia National Labs. Protocells are designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides, and small molecules. Alpine Biosciences was sold to Cascadian Therapeutics (NASDAQ:CASC) in August of 2014.

Acquired by